RPRX
Royalty Pharma plc
$52.96
-$0.74(-1.38%)
79
Overall
100
Value
83
Tech
55
Quality
Market Cap
$16.52B
Volume
8.61M
52W Range
$34.08 - $56.50
Target Price
$59.57
Company Overview
| Mkt Cap | $16.52B | Price | $52.96 |
| Volume | 8.61M | Change | -1.38% |
| P/E Ratio | 21.4 | Open | $54.38 |
| Revenue | $2.4B | Prev Close | $53.70 |
| Net Income | $770.9M | 52W Range | $34.08 - $56.50 |
| Div Yield | 0.94% | Target | $59.57 |
| Overall | 79 | Value | 100 |
| Quality | 55 | Technical | 83 |
No chart data available
About Royalty Pharma plc
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Sector: Industrials
Industry: Medicinal and Botanical Manufacturing
Latest News
Royalty Pharma Shareholders Back Board, Pay and Flexibility
TipRanks Auto-Generated Newsdesk•16 days ago
Royalty Pharma Secures New $1.8 Billion Credit Facility
TipRanks Auto-Generated Newsdesk•23 days ago
Royalty Pharma Secures New $1.8 Billion Credit Facility
TipRanks Auto-Generated Newsdesk•23 days ago
Analysts’ Top Healthcare Picks: Amneal Pharmaceuticals (AMRX), Immunovant (IMVT)
Christine Brown•25 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | RPRX | $52.96 | -1.4% | 8.61M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |